Here, we developed MMP‐2‐sensitive FTH1 NCs—specifically TmSm‐modified FTH1 NCs carrying YM155 (FTS/YM155 NCs)—for the codelivery of YM155 and TmSm to synergistically inhibit survivin activity at both the transcript and protein levels (Figure 1) at a tumor‐specific site. The gene discussed is MMP2; the disease is neoplasm.